Medicines Discovery Catapult’s Post

Read the Editorial Commentary on MET targeted therapy in non-small cell lung cancer patients with MET exon 14-skipping mutations by Edyta Maria Urbanska, Jens Mollerup, and Jan Trøst Jørgensen and recently published in Translational Lung Cancer Research (Open Access): https://lnkd.in/dM5F5KvZ #medicine #pharmaceuticals #oncology #precisionmedicine #biomarkers

Learn about ADC discovery in cancer, from synthesis to safety and efficacy studies, in an upcoming webinar with Charles River experts.

Learn about ADC discovery in cancer, from synthesis to safety and efficacy studies, in an upcoming webinar with Charles River experts.

𝗛𝗲𝗺𝗲𝗿𝗶𝗼𝗻 𝗶𝘀 𝗮𝗰𝗵𝗶𝗲𝘃𝗶𝗻𝗴 𝘀𝗶𝗴𝗻𝗶𝗳𝗶𝗰𝗮𝗻𝘁 𝗿𝗲𝘀𝘂𝗹𝘁𝘀 Hemerion Therapeutics continues advancing rapidly in its ongoing #clinicaltrial for glioblastoma, which is the most common and aggressive type of brain cancer. The completion of the trial would have a major positive impact on the company's valuation, increasing the chances of a buyout and leading to substantial #returns for #investors, with estimations in the range of 15x. 🚀 Hemerion's therapy targets a type of cancer that currently has no effective treatments, and could be on an accelerated pathway to FDA approval in the next two years. 📲 Invest in Hemerion Therapeutics here: https://bit.ly/4fgPdvx

Read the full case study at the link below and visit us at #ASCO24 Booth 33168 to dive deeper into our findings!

At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, independent investigators presented preclinical data demonstrating the therapeutic potential of Cyclacel Pharmaceuticals, Inc. fadraciclib in colorectal cancer models. Fadraciclib significantly inhibited tumor growth, triggered apoptosis, and induced anaphase catastrophe in patient-derived organoids (PDOs) and xenografts (PDX). These findings support fadraciclib's potential as a novel treatment in multiple tumor types by targeting key molecular features of cancer. Learn more: https://bit.ly/3YliEaC #CancerResearch #Biotech #Innovation

Hox Therapeutics and Vernalis enter collaboration to advance oncology drug discovery. Partnership focuses on uncovering #SmallMolecule inhibitors for #cancer treatment. As mentioned on their website, "Vernalis will use its state-of-the-art protein science and Hit ID platforms to produce the target protein, and to identify and characterise small molecule inhibitors of the target." This collaboration marks a significant step forward in the development of targeted therapies for cancer, promising to accelerate the discovery and development of novel treatments with the potential to significantly impact patient care in #oncology.

🧬✨ Case Study Highlight: Discovering the impact of next-generation sequencing (NGS) on treatment decisions in oncology. “What do cancer patients understand about next-generation sequencing?” This is the question an Inspire client wanted to answer. Using RWD on the Inspire platform, research uncovered how patients use NGS information to guide decisions. Highlights include: 📝 Most patients believe information from NGS determines their treatment 🩺 50% of respondents used NGS information to search for clinical trials and treatments Read the full case study at the link below and visit us at Booth 33168 to dive deeper into our findings! https://ow.ly/yZW350RY8Wq Want to schedule time with our team? https://lnkd.in/esvAu2YJ #ASCO24 #PrecisionMedicine #Oncology #NGS #PatientVoice

Learn about ADC discovery in cancer, from synthesis to safety and efficacy studies, in an upcoming webinar with Charles River experts.

Fadraciclib (formerly CYC065) from Cyclacel Pharmaceuticals, Inc. is a highly selective and potent CDK2/9 inhibitor, currently being evaluated in clinical trials for solid tumors and lymphoma. By inhibiting CDK2 and CDK9 fadraciclib causes apoptotic death through anaphase catastrophe of cancer cells at sub-micromolar concentrations. The study is currently enrolling the biomarker cohort for patients prospectively selected for CDKN2A/CDKN2B alterations and the T-cell lymphoma. cohort. Explore more about the potential of Fadraciclib: https://bit.ly/4gfCZ7K #CancerResearch #Biotech #HealthcareInnovation